Abstracts
Twenty three patients with Cutaneous Larva Migrans syndrome were prospectively treated with 400 mg/day of Albendazole for 3 consecutive days. Clinical response, compliance and tolerance was excellent. Patients were asymptomatic within the first 72 hours of treatment and recurrences did not occurred. Preliminary results with three additional patients suggest that a single oral 400 mg dose may be effective as well.
Cutaneous larva migrans; Treatment; Albendazole
Veintitrés pacientes con el sindrome de Larva Cutanea Migratoria, fueron tratados prospectivamente con 400 mg/dia VO de albendazol por tres dias consecutivos. La respuesta clínica, aceptación y tolerancia del tratamiento fué excelente. Todos los pacientes se volvieron asintomáticos durante las primeras 72 horas de tratamiento y no se observaron recurrencias de lesiones. Los resultados preliminares obtenidos entres pacientes adicionales, sugieren que la dosis única de 400 mg puede ser igualmente efectiva.
PRELIMINARY REPORT
Treatment of Cutaneous Larva Migrans with albendazole. Preliminary report
Tratamiento del Síndrome de Larva Cutanea Migratoria con Albendazol. Reporte Preliminar
Jaime R. Torres R.; Angel R. Orihuela; David Garcia; Salha Abdul-Hadi
Address for correspondence Address for correspondence: Salha Abdul-Hadi Instituto de Medicina Tropical Universidad Central de Venezuela Apartado 2109, Caracas, Venezuela
SUMMARY
Twenty three patients with Cutaneous Larva Migrans syndrome were prospectively treated with 400 mg/day of Albendazole for 3 consecutive days. Clinical response, compliance and tolerance was excellent. Patients were asymptomatic within the first 72 hours of treatment and recurrences did not occurred. Preliminary results with three additional patients suggest that a single oral 400 mg dose may be effective as well.
Key words: Cutaneous larva migrans; Treatment; Albendazole.
RESUMEN
Veintitrés pacientes con el sindrome de Larva Cutanea Migratoria, fueron tratados prospectivamente con 400 mg/dia VO de albendazol por tres dias consecutivos. La respuesta clínica, aceptación y tolerancia del tratamiento fué excelente. Todos los pacientes se volvieron asintomáticos durante las primeras 72 horas de tratamiento y no se observaron recurrencias de lesiones. Los resultados preliminares obtenidos entres pacientes adicionales, sugieren que la dosis única de 400 mg puede ser igualmente efectiva.
Texto completo disponível apenas em PDF.
Full text available only in PDF format.
Recebido para publicação em 20/5/1988.
- 1. BEAVER, P. C. - Larva Migrans. Exp. Parasit., 5: 587-594, 1956.
- 2. BOHPALE, G. M. & BHATNAGAR, B. J. - The efficacy of some newer broad spectrum antihelminthics against third-stage larvae of Ancylostoma caninum in the mouse. J. Helminth., 59: 307 311, 1985.
- 3. CLINE, B. L.; LITTLE, M. D.; BARTHOLOMEW, R. K. & HALSEY, N. A. - Larvicidal activity of albendazole against Necator americanus in human volunteers. Amer J. trop. Med. Hyg., 33: 387-394, 1984.
- 4. DAVIS, C. M. & ISRAEL, R. M. - Treatment of creeping eruption with topical thiabendazole. Arch. Derm., 97: 325-329, 1968.
- 5. WINTER P. A. & FRIPP, P. J. - Treatment of cutaneous larva migrans (sandworm disease). S. Afr. med. J., 52: 556-559, 1978.
- 6. WRIGHT, D. O. & GOLD, E. M. - Loeffler's syndrome associated with creeping eruption. Arch, intern. Med., 78: 303-310, 1946.
Publication Dates
-
Publication in this collection
18 Feb 2011 -
Date of issue
Feb 1989
History
-
Received
20 May 1988
